AzTrials
AzTrials

Rib FracturesNCT03540095

Erector Spinae Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain

A study testing Erector Spinae Plane Block and Paravertebral Nerve Block in people with Rib Fractures and Pain, Acute, run by University of Pittsburgh at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Continuous paravertebral analgesia and erector spinae plane blockade (ESP) are accepted techniques at University of Pittsburgh Medical Center (UPMC) for the management of thoracic pain following surgery and trauma. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Rib Fractures, Pain, Acute, Thoracic Injuries
What is being tested?
Erector Spinae Plane Block and Paravertebral Nerve Block
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7 participants
Where
1 siteUnited States
Study dates
23 Jul 2018to 7 May 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age between 18-85 years
  • no contraindications to the placement of a paravertebral catheter or erector spinae plane catheter
  • American Society of Anesthesiologists physical status between I-IV
  • no chronic opioid use
  • patients who are not expected to be on therapeutic anticoagulants post-procedurally
  • no clopidogrel in last 48 hours
Show all 11Show fewer
  • no known allergies to any of the drugs/agents used study protocol
  • no personal or family history of malignant hyperthermia
  • not pregnant
  • not having an altered mental status (oriented to place, person, or time)
  • no comorbid condition(s) that in the judgment of the anesthesiologist, would preclude the patient from any aspect of the study. Comorbid conditions include bleeding disorders, thrombocytopenia, localized infection, sepsis, possibly abnormalities of the thoracic spine or paravertebral anatomy neoplastic mass occupying the paravertebral space, empyema, allergy to local anesthestic drug, increased intracranial pressure, severe uncorrected hypovolemia, fixed cardiac output states.

Who cannot join

  • Age younger than 18 years or older than 85 years
  • any contraindication to the placement of a paravertebral or erector spinae catheters
  • American Society of Anesthesiologists physical status V or greater
  • chronic opioid use
  • coagulation abnormalities or patients who are expected to be on therapeutic anticoagulants postprocedurally
  • clopidogrel use within 48 hours
Show all 11Show fewer
  • allergy to any of the drugs/agents used study protocol
  • personal or family history of malignant hyperthermia
  • pregnancy
  • having an altered mental status (not oriented to place, person, or time), (11) any comorbid condition that in the judgment of the anesthesiologist would preclude the patient from any aspect of the study
  • patient refusal. Comorbid conditions include bleeding disorders, thrombocytopenia, localized infection, sepsis, possibly abnormalities of the thoracic spine or paravertebral anatomy neoplastic mass occupying the paravertebral space, empyema, allergy to local anesthetic drug, increased intracranial pressure, severe uncorrected hypovolemia, fixed cardiac output states.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Pittsburgh Medical Center - Presbyterian Hospital

    Pittsburgh, Pennsylvania, 15213

Other trials in United States

About this study

Official title: Randomized Prospective Clinical Trial of Erector Spinae Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain

Continuous paravertebral analgesia and erector spinae plane blockade (ESP) are accepted techniques at University of Pittsburgh Medical Center (UPMC) for the management of thoracic pain following surgery and trauma. Recently, an increasing number of erector spinae plane blocks are being performed as it has been demonstrated in our institution and via case reports that they provide clinical effectiveness, but may have a better side-effect profile than the paravertebral nerve block. However, the relative efficacy of ESP and continuous paravertebral analgesia for patients with rib fractures remains to be established. This study will include 60 consecutive patients presenting to the UPMC Presbyterian Acute Interventional Perioperative Pain Service suffering from unilateral rib fractures and will be randomized to receive either nerve blocks via continuous paravertebral infusion or via erector spinae plane infusion. In addition, to treat breakthrough pain, the patients in both arms will receive multimodal adjunctive therapy per routine. Bupivicaine and ropivicaine are FDA approved for use in nerve block catheters. The primary outcome will be total opioid consumption in the first 3 days of nerve block. Secondary outcomes include highest visual analog pain score (VAS) with deep breathing and at rest, adverse events, and total number of nerve blocks. Other data points include time to readiness for discharge, and length of hospital stay.

Read the detailed description

All interventions regarding the placement and management of ESP and paravertebral blocks in this study are consistent with existing standard of care practices at UPMC and utilize protocols that are already in use. In addition, by nature of being included in a research study, patients are likely to receive closer monitoring for side-effects.

Screening and enrollment: After approval by the institutional review board, all (American Society of Anesthesiology) ASA I-IV patients aged 18-85 years, weighing between 50 and 120 kg with unilateral rib fractures will be screened for enrollment. Sixty patients will be enrolled in this randomized prospective study with equal numbers in each arm of the trial. This study design is unblinded as we cannot blind patients nor observers as to the type of block performed (slightly different location). This is an accepted limitation of the study. No advertising will be used and no monetary compensation will be offered. The nature of the study, planned interventions, risks, benefits, and alternatives will be discussed in detail with the patients at the time of enrollment and prior to the patients' signing of a written consent form.

Randomization: Patients will be enrolled into one of the study groups on the day of consultation in an alternating fashion. The study groups are defined as: Group I: Erector Spinae Plane Block (ESP) 30 patients Group II: Paravertebral Block (PVB) 30 patients.

Day of Block: After written informed consent is confirmed, a research assistant will introduce the scoring system used for pain assessment (VAS), and demonstrate proper use of the incentive spirometer.

All nerve blocks will be performed by an experienced member of UPMC's pain management service. Both nerve blocks can take between 10-60 minutes to perform. They will either occur in the ICU or on a monitored medicine floor.

Paravertebral nerve block catheter placement and activation (PVB group only): Paravertebral catheters will be placed according to UPMC standard of care practices as outlined below: After an intravenous catheter has been established and standard monitors and oxygen applied, the patient will be placed in the sitting position. The patient will be administered appropriate sedation based on the discretion of the provider if needed to safely perform the procedure.

Paravertebral technique: With the patient in a sitting position, the point of needle entry will be marked on the skin corresponding to paravertebral catheter placement. The thoracic spine level will be at the anatomic level corresponding to the ribs fractured. The needle entry sites will be 2.5 cm lateral to the midpoint of the spinous process of the corresponding thoracic vertebrae. The area will be prepped and draped in a sterile fashion, and 1% lidocaine infiltrated subcutaneously at each point of anticipated needle entry. For each of the catheter placement, a sterile gauge Tuohy needle will be introduced with ultrasound guidance towards the paravertebral space. After final needle placement, a hanging drop technique will be used to assess for interpleural placement while the patient inhales and exhales deeply. Next 5 mL of ropivicaine 0.5% will be injected incrementally through each needle after negative aspiration under ultrasound visualization, followed by insertion of the nerve block catheter to a depth 5 cm beyond the tip of the needle. An additional 20 mL of ropivicaine 0.5% will then be injected in 5 mL increments with negative aspiration in between, through each catheter yielding a total activation dose of 25 ml of ropivicaine 0.5% via each catheter. The catheters will be secured with Steri-strips and a transparent occlusive dressing. Vital signs will be monitored at regular intervals until the procedure is complete.

Erector spinae catheter placement and activation (ESP group only): An erector spinae plane catheter will be placed according UPMC standard of care practices as outlined below: After an intravenous infusion has been established and standard monitors and oxygen applied, the patient will be placed in the sitting position. The patient will be administered appropriate sedation based on the discretion of the provider if needed to safely perform the procedure.

ESP technique: With the patient in a sitting position, the point of needle entry will be marked on the skin corresponding to the appropriate vertebral level relative to the rib fractures. The area will be prepared and draped in a sterile fashion, and 1% lidocaine infiltrated subcutaneously at the point of anticipated needle entry. A sterile Tuohy needle will be introduced and advanced towards the corresponding transverse process. Hydrodissection will ensure that the proper plane is located. Once the erector spinae musculature is separated from the rib, 25ml of ropivicaine 0.5% will be introduced into the plane under ultrasound guidance. A catheter will be placed to a depth 5 cm beyond the tip of the needle. The catheter will be secured with Steri-strips and a transparent occlusive dressing. Vital signs will be monitored at regular intervals until the procedure is completed.

Paravertebral infusions of Bupivicaine 0.0625% will be titrated to 12 ml/hr maximum for the patients in the paravertebral catheter group (Group PVB). Patients in the ESP group (ESP) will start a continuous infusion of Bupivicaine 0.0625% and titrate to 12 mL/hr maximum as needed for pain. The patients in both groups will also be given access to acetaminophen 1000 mg every 6 hours IV or PO if there is no contraindication. Other adjuncts such as gabapentin, celebrex, ketamine, and opioid analgesics may be adjusted by the physicians involved based on the patients clinical condition. A PCA may be required for opioid pain medication administration initially, and will be continued until the patient is able to tolerate oral pain medication. Additional pain relief is available via nurse-administered 3 mL boluses of 0.0625% bupivacaine via the catheter pumps.

Post nerve block anesthesia protocol: Once on the floors, additional pain relief is available via nurse-administered 3 mL boluses of Bupivicaine via the catheter pumps given no more than hourly. All patients will be assessed daily by members of the acute interventional perioperative pain service. The infusion rates via the paravertebral and ESP catheters may be adjusted at the discretion of the pain service up to a rate of 12 mL/hr on each side (standard infusion rate used at UPMC-Presbyterian). All paravertebral ESP catheters will be stopped and removed as tolerated by the patient or post-procedure day #5, whichever occurs first. Additional pain medication will be available to all patients per standard of care.

ICU (Intensive Care Unit): Patients will be admitted to an intensive care unit at the discretion of the emergency department. Patients who are intubated and sedated, and who are unable to participate medical decision making will not be accepted for this study. If a patient fits the inclusion criteria and is in the ICU, the nerve block will be placed and managed in the ICU as above for all other situations.

Data will be collected daily from the patients until the nerve block is removed or 5 days post-procedure, whichever comes first.

Discharge: The readiness for discharge will be determined by the primary team: This decision will likely include (1) return of respiratory function, (2) hemodynamic stability, (3) normothermia, (4) no clinical evidence of DVT/PE (Deep Vein Thrombosis/Pulmonary Embolism) which is untreated, (5) pain controlled by oral agents. In addition, actual length of hospital stay will be recorded. Nerve block will be performed and the catheters will be removed according to the ASRA (American Society of Regional Anesthesia and Pain Medicine) guidelines for regional anesthesia catheter placement and removal available on the ASRA website.

Being tested
Erector Spinae Plane Block, Paravertebral Nerve Block
Medical subject headings
Rib Fractures, Acute Pain, Thoracic Injuries, Neuralgia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Erector Spinae Plane BlockDrug

    Also called Ropivicaine 0.5%, Bupivicaine 0.0625%, Braun 18 Ga x 3.5 in TUOHY Epidural Needle, Braun 20 Ga CLOSED TIP CATHETER

    See arm description

  • Paravertebral Nerve BlockDrug

    Also called Ropivicaine 0.5%, Bupivicaine 0.0625%, Braun 18 Ga x 3.5 in TUOHY Epidural Needle, Braun 20 Ga CLOSED TIP CATHETER

    See arm description

Study groups in NCT03540095
Study groupRoleWhat they receive
Erector Spinae Plane BlockExperimentalThe patients randomized to the Erector Spinae Plane Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
Receives: Drug: Erector Spinae Plane Block
Paravertebral Nerve BlockExperimentalThe patients randomized to the Paravertebral Nerve Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
Receives: Drug: Paravertebral Nerve Block

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Opioid Consumption

    Measured: first 72 hours after intervention

Secondary outcomes (5)
  1. Visual Analog Scale (VAS) Pain Scores

    Visual Analog Scale is numerical from 0-10, with 10 being the worst pain imaginable, and 0 being no pain. The pain score will be recorded at rest and with deep breathing at the time intervals below. There are no subscales involved in this measurement. Simply, we will record single pain scores by VAS scale at rest and with deep breathing at indicated times.

    Measured: Immediately prior to intervention. 15 minutes after intervention. 60 minutes after intervention. Daily (in morning) for 3 total days after intervention.

  2. Adverse Events

    We will record total number of pneumothoraxes, site infections, significant bleeding events, and unintentional catheter removals. Each of these events will be added separately per patient. We will analyze how many patients experience any adverse effect, and then further study the incidence of each specific adverse effect and compare them across both interventions.

    Measured: During the expected duration of this study, which is on average 5 days.

  3. Number of Nerve Blocks

    The provider will use his/her judgement to determine how many nerve blocks are required for management of the rib fracture pain. Compare the number of nerve blocks required for each type of intervention in the separate arms.

    Measured: During the expected duration of this study, which is on average 5 days.

  4. Length of Stay

    Total length of hospitalization

    Measured: Will evaluate length of stay upon termination of the last study subject. Expected to be within 6 months of initiation of the trial.

  5. Time until discharge

    Time from intervention to discharge from hospital

    Measured: Will evaluate length of stay upon termination of the last study subject. Expected to be within 6 months of initiation of the trial.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 May 2018
  2. Study start23 Jul 2018
  3. Primary completion7 May 2019
  4. Study completion7 May 2019

Why it stopped: Due to staffing issues, we are unable to enroll patients at the clinical site assigned. The study is terminated.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
There are two arms. Our 60 patients will be randomized to either of the two arms and studied in parallel.
Masking
None (open label)
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03540095
Sponsor's protocol ID
PRO18040578
Status last verified
May 2019
First submitted
16 May 2018
Last updated
16 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Erector Spinae Plane Block and Paravertebral Nerve Block in people with Rib Fractures and Pain, Acute, run by University of Pittsburgh at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 16 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Due to staffing issues, we are unable to enroll patients at the clinical site assigned. The study is terminated.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Opioid Consumption (time frame: first 72 hours after intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2019; AzTrials last refreshed its copy on 2 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in